Nabriva appoints new chief medical officer
This article was originally published in Scrip
Nabriva Therapeutics, an Austrian biotechnology company focused on developing antibiotics for serious infections caused by resistant pathogens, has appointed Dr William Prince chief medical officer. He joins from Surface Logix, where he was chief development officer.
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.